JPMorgan Chase & Co. Reaffirms Overweight Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “overweight” rating reissued by research analysts at JPMorgan Chase & Co. in a report released on Wednesday,Digital Look reports.

Several other research firms have also recently issued reports on AZN. Berenberg Bank reissued a “buy” rating and set a GBX 140 ($1.77) target price on shares of AstraZeneca in a research note on Monday, January 27th. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research note on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of GBX 7,542.80 ($95.15).

AstraZeneca Trading Down 0.2 %

AZN stock traded down GBX 28 ($0.35) during midday trading on Wednesday, hitting £117.60 ($148.35). 24,679,291 shares of the company’s stock were exchanged, compared to its average volume of 27,183,740. The business has a 50-day simple moving average of £109.29 and a two-hundred day simple moving average of £114.68. The company has a current ratio of 0.93, a quick ratio of 0.59 and a debt-to-equity ratio of 73.83. The stock has a market capitalization of £226.27 billion, a PE ratio of 32.23, a P/E/G ratio of 0.86 and a beta of 0.17. AstraZeneca has a 1-year low of GBX 9,670 ($121.99) and a 1-year high of £133.88 ($168.89).

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.